Prime Highlights
- Lippuner said healthcare organisations that deliver the best end-to-end patient experience would be the ones to lead over the next decade.
- Revaia’s Morgan Kessous described Semble as exceptionally well positioned to lead Europe’s reshaping healthcare market.
Key Facts
- Semble, founded in 2016 and headquartered in London, was previously known as Heydoc before rebranding.
- The global healthcare IT market was valued at $866.48 billion in 2025 and is projected to reach $2.86 trillion by 2033.
Background
London-based healthcare technology company Semble has raised £30 million in a Series C funding round led by European growth investor Revaia, with participation from Partech, Mercia Ventures, and Octopus Ventures. The round brings Semble’s total funding to approximately £57 million.
Semble’s platform currently serves 1,700 healthcare businesses across 80 specialities, reaching 10 million patients in the UK, roughly one in six people. Over 16,000 healthcare professionals use the software daily. Customers include Nuffield Health, London Doctors Clinic, and Modality.
The company targets a core problem in private outpatient healthcare: fragmented software systems that cannot communicate with each other. Semble replaces these with a single platform covering scheduling, billing, clinical records, prescriptions, and patient communications. It connects with over 1,200 external tools, including diagnostics and lab systems.
CEO and co-founder Christoph Lippuner said the healthcare industry had long relied on disconnected solutions that added complexity for providers and disrupted the patient experience. He said organisations that deliver the best end-to-end patient experience would lead the next decade.
Revaia partner Morgan Kessous said Semble is building a system of action for modern healthcare, with genuine clinical depth and the trust of providers across the UK and France.
France is Semble’s first international market, where it has already established regulatory credibility. The fresh capital will support further European expansion. The company has more than doubled its headcount since late 2024 and was named by TIME as one of the best healthtech companies in the world for 2025.
